SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Guren T.)
 

Sökning: WFRF:(Guren T.) > Treatment and survi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003662naa a2200553 4500
001oai:DiVA.org:umu-152271
003SwePub
008181002s2018 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:139100441
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1522712 URI
0247 a https://doi.org/10.1038/s41416-018-0215-62 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1391004412 URI
040 a (SwePub)umud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Claassen, Yvette H. M.4 aut
2451 0a Treatment and survival of rectal cancer patients over the age of 80 years :b a EURECCA international comparison
264 c 2018-07-30
264 1b Nature Publishing Group,c 2018
338 a print2 rdacarrier
520 a BACKGROUND: The optimal treatment strategy for older rectal cancer patients remains unclear. The current study aimed to compare treatment and survival of rectal cancer patients aged 80+.METHODS: Patients of >= 80 years diagnosed with rectal cancer between 2001 and 2010 were included. Population-based cohorts from Belgium (BE), Denmark (DK), the Netherlands (NL), Norway (NO) and Sweden (SE) were compared side by side for neighbouring countries on treatment strategy and 5-year relative survival (RS), adjusted for sex and age. Analyses were performed separately for stage I-III patients and stage IV patients.RESULTS: Overall, 19 634 rectal cancer patients were included. For stage I-III patients, 5-year RS varied from 61.7% in BE to 72.3% in SE. Proportion of preoperative radiotherapy ranged between 7.9% in NO and 28.9% in SE. For stage IV patients, 5-year RS differed from 2.8% in NL to 5.6% in BE. Rate of patients undergoing surgery varied from 22.2% in DK to 40.8% in NO.CONCLUSIONS: Substantial variation was observed in the 5-year relative survival between European countries for rectal cancer patients aged 80+, next to a wide variation in treatment, especially in the use of preoperative radiotherapy in stage I-III patients and in the rate of patients undergoing surgery in stage IV patients.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Vermeer, Nina C. A.4 aut
7001 a Iversen, Lene H.4 aut
7001 a van Eycken, Elizabeth4 aut
7001 a Guren, Marianne G.4 aut
7001 a Mroczkowski, Pawel4 aut
7001 a Martling, Annau Karolinska Institutet4 aut
7001 a Codina Cazador, Antonio4 aut
7001 a Johansson, Robertu Umeå universitet,Onkologi4 aut0 (Swepub:umu)rojo0001
7001 a Vandendael, Tamara4 aut
7001 a Wibe, Arne4 aut
7001 a Møller, Bjørn4 aut
7001 a Lippert, Hans4 aut
7001 a Rutten, Harm J. T.4 aut
7001 a Portielje, Johanneke E. A.4 aut
7001 a Liefers, Gerrit J.4 aut
7001 a Holman, Fabian A.4 aut
7001 a van de Velde, Cornelis J. H.4 aut
7001 a Bastiaannet, Esther4 aut
7102 a Karolinska Institutetb Onkologi4 org
7730 t British Journal of Cancerd : Nature Publishing Groupg 119:4, s. 517-522q 119:4<517-522x 0007-0920x 1532-1827
8564 u https://www.nature.com/articles/s41416-018-0215-6.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-152271
8564 8u https://doi.org/10.1038/s41416-018-0215-6
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:139100441

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy